Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains

US6664227B1 · kind B1 · utility

Assignees

• Genetics Institute, LLC · US
• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Thomas Andrew Wynn · Lexington, US
• Monica G. Chiaramonte · Rockville, US
• Mary Collins · Natick, US
• Debra Donaldson · Cambridge, US
• Lori Fitz · Arlington, US
• Tamlyn Neben · Acton, US
• Matthew Whitters · Hudson, US
• Clive Wood · Boston, US

Key dates

• Filing date: Nov 29, 1999
• Grant date: Dec 16, 2003
• Expiry date: Nov 29, 2019

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.